Ventrus Biosciences Inc. fell the most ever after it stopped development of a drug meant to treat hemorrhoidal disease. The New York City company has no products on the market; two other compounds are in the second of three phases of clinical testing. A study of the hemorrhoid treatment iferanserin in 603 patients found their bleeding, itching, and pain failed to improve.